Skip to main content
SBFM
NASDAQ Life Sciences

Sunshine Biopharma Seeks 7,000,000-Share Equity Plan Increase at Dec 29 Meeting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.8
Mkt Cap
$2.161M
52W Low
$2.53
52W High
$464
52W Position info
11% above low
Off High info
99% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

SBFM is trading near its 52-week low of $2.53 (11% above the low) on light trading volume (0.2× avg).

Summary

Sunshine Biopharma's definitive proxy asks shareholders to approve expanding its 2023 equity plan to 7,000,000 shares — about 8.5x the 823,772 common shares outstanding — at a December 29 virtual meeting, alongside director elections and auditor ratification. The CEO's Series B preferred (1,000 votes per share) controls the vote.


Key Events · Corporate Governance and Compliance · SBFM

  • Equity Plan Expansion to 7,000,000 Shares

    Proposal 3 would raise the 2023 Equity Incentive Plan authorization from 3,415 shares (reverse-split adjusted) to 7,000,000 shares. No shares remain available under the plan today; all 3,415 previously authorized shares were issued to one director in April and August 2026.

  • Potential Overhang vs Share Count

    The 7,000,000-share authorization equals roughly 8.5x the 823,772 common shares outstanding on the November 4, 2026 record date (7,000,000 / 823,772 = ~8.5). No awards have been granted under the increase; the dilution is potential, not actual.

  • CEO Controls the Vote

    Dr. Steve N. Slilaty holds all 130,000 Series B Preferred shares, each carrying 1,000 votes, giving him 100% of that class and effective control of every proposal regardless of common-holder votes.

  • Board Change: Sokhn In, Keller Out

    Andre Sokhn, a healthcare commercial executive, is nominated as a new independent director. Dr. Andrew Keller is not standing for reelection; the board stays at five seats.


Analysis · SBFM · Life Sciences

The headline item is Proposal 3: raising the 2023 Equity Incentive Plan authorization from 3,415 shares (post-reverse-split adjusted) to 7,000,000 shares. Against 823,772 common shares outstanding on the November 4 record date, that authorization is roughly 8.5x the entire current common share count — a large potential overhang if the plan is fully used, though no awards have been granted and the plan is currently empty. The proxy also nominates Andre Sokhn to replace departing director Dr. Andrew Keller, and asks holders to ratify M&K CPAS as FY2026 auditor. Governance context matters here: the CEO holds all 130,000 Series B preferred shares at 1,000 votes each, so he controls the outcome of every proposal regardless of common-holder votes. The company has completed three reverse splits in three years to hold its Nasdaq listing, and the pay-versus-performance table shows a fixed $100 investment worth $0 across 2023-2025.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SBFM was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $2.53 to $464.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SBFM - Latest Insights

SBFM
Nov 12, 2026, 11:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $2.70 info
Change: $0 (0%) info
Market Cap: $2.161M info
SBFM
Nov 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.70 info
Change: -$0.110 (-4%) info
Market Cap: $2.161M info
SBFM
Oct 22, 2026, 9:25 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.1638
Real-time Price: $2.70 info
Change: Reverse Stock Split info
Market Cap: $2.161M info
SBFM
Oct 14, 2026, 5:21 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.232
Real-time Price: $2.70 info
Change: Reverse Stock Split info
Market Cap: $2.161M info
SBFM
Oct 09, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3269
Real-time Price: $2.70 info
Change: Reverse Stock Split info
Market Cap: $2.161M info